• CR Pharmaceutical Holdings, a wholly owned subsidiary of China Resources Pharmaceutical Group, reported unaudited nine-month results through September 30, 2026.
• Consolidated net profit fell to RMB 6.97 billion from RMB 7.56 billion a year earlier.
• Profit attributable to parent-company owners declined to RMB 2.39 billion from RMB 2.56 billion.
• Revenue rose to RMB 203.53 billion from RMB 200.88 billion.
• Operating cash flow dropped to RMB 4.85 billion from RMB 6.07 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261028-12385893), on October 28, 2026, and is solely responsible for the information contained therein.